Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting
Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting
Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting
Submitted by
admin
on June 1, 2014 - 11:54am
Source:
Yahoo/BusinessWire
News Tags:
SGN-CD19A
Seattle Genetics
non-Hodgkin's lymphoma
Headline:
Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate (ADC) SGN-CD19A in Non-Hodgkin Lymphoma at ASCO Annual Meeting
Do Not Allow Advertisers to Use My Personal information
